RWJ 442831

Drug Profile

RWJ 442831

Alternative Names: RWJ-442831

Latest Information Update: 29 Aug 2007

Price : $50

At a glance

  • Originator Essential Therapeutics [CEASED]
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC
  • Class Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections pharmacodynamics section
  • 04 Oct 2004 Essential Therapeutics has closed down
  • 24 Sep 2003 Preclinical data presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the pharmacokinetics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top